PFAS Lawsuit Update Today: 2026 Settlement & Claims Guide

Quick Answer
– What is this case: Thousands of personal injury and municipal water contamination claims consolidated in MDL 2873 before Judge Richard M. Gergel in the U.S. District Court for the District of South Carolina, alleging that PFAS "forever chemicals" manufactured by 3M, DuPont, and others caused cancer and serious illness.
– Who qualifies: Individuals diagnosed with specific PFAS-linked cancers or conditions who had documented exposure through contaminated drinking water, AFFF firefighting foam, or proximity to industrial PFAS manufacturing or use sites.
– What it's worth: Individual claimant payouts vary by disease category and severity. Early projections from the personal injury track range from $50,000 to over $500,000 per claimant depending on illness type, duration of exposure, and individual damages. The 3M municipal water settlement fund totals $10.3 billion. The DuPont/Chemours/Corteva fund totals approximately $1.185 billion.

Case Snapshot

PFAS Lawsuit Update Today: Where the Litigation Stands in 2026

The PFAS lawsuit is among the largest active mass tort proceedings in U.S. federal court history. As of 2026, MDL 2873 continues before Judge Richard M. Gergel in Charleston, South Carolina, with the municipal water system settlement track in active distribution and the personal injury track moving toward additional bellwether trials.

Two headline settlements have already been approved. The 3M Company settlement, valued at $10.3 billion and paid out over a 13-year period ending in 2036, covers claims by public water systems across the United States. DuPont de Nemours, Chemours, and Corteva reached a combined settlement of approximately $1.185 billion covering similar municipal claims.

This is also helpful: Roundup Cancer Lawsuit 2026: Claims, Payouts & Deadlines

Neither settlement fully resolves individual personal injury claims. Those cases remain active. Claimants who were diagnosed with cancer or another linked illness after PFAS exposure are still in the process of filing, and the litigation is far from over.

The scale of this litigation is significant. Over 6,000 cases were pending in MDL 2873 before the major settlements were reached. The personal injury docket continues to grow as more individuals learn of their PFAS exposure history and receive diagnoses.

*Attorney Insight: Attorneys handling these claims note that the municipal water settlement's approval does not preclude individual injury victims from pursuing separate compensation through the personal injury track, which operates on a different claims structure and timeline.*

PFAS Lawsuit News Today: Key Developments Entering 2026

The most significant development entering 2026 is the transition of MDL 2873's municipal water track from settlement negotiation to active claims distribution. Water utilities and public water systems that opted into the 3M and DuPont settlements began receiving allocation payments through a court-supervised claims process.

The personal injury track is running on a separate schedule. Judge Gergel has moved to select additional bellwether cases to test the strength of individual injury claims before broader resolution. These bellwether trials function as test cases.

The results of bellwether trials shape global settlement negotiations. Plaintiffs' attorneys and defense counsel both watch these outcomes to calibrate the value of the broader inventory of claims.

*Attorney Insight: Attorneys handling these claims note that the EPA's April 2024 finalization of maximum contaminant levels for six PFAS compounds has strengthened causation arguments in personal injury cases, giving plaintiffs a federal regulatory standard to anchor their exposure claims.*

PFAS Lawsuit Update: The Full Procedural History of MDL 2873

MDL 2873 was created by the Judicial Panel on Multidistrict Litigation and assigned to Judge Gergel in December 2018. The consolidation brought together claims from municipalities, water utilities, and individual plaintiffs alleging harm from PFAS contamination.

The litigation proceeded through years of discovery, expert battles, and pretrial motions. The first bellwether trial was set for 2023 against 3M. That trial never took place. 3M entered settlement negotiations and finalized the $10.3 billion agreement before jury selection.

The early settlement reflects the litigation risk both sides faced. PFAS contamination evidence was strong, and the plaintiffs' scientific causation case was well-developed.

Key Procedural Milestones:

• December 2018: MDL 2873 created and assigned to Judge Gergel
• 2019-2022: Discovery and expert depositions
• June 2023: 3M announces $10.3 billion settlement
• July 2023: DuPont/Chemours/Corteva announce $1.185 billion settlement
• 2024: Both municipal settlements receive court approval
• 2025-2026: Personal injury and AFFF tracks continue under active case management

*Attorney Insight: Attorneys handling these claims point out that the speed of the 3M settlement, reached before the first bellwether trial concluded, signals the defendants' awareness of substantial litigation exposure in front of a South Carolina jury.*

PFAS MDL 2873 Update: What the Docket Shows in 2026

MDL 2873's docket reflects an evolving, multi-track proceeding. The case caption is *In re: Aqueous Film-Forming Foams Products Liability Litigation*, filed in the District of South Carolina.

Judge Gergel has issued numerous case management orders governing discovery protocols, expert witness standards, and trial scheduling. His case management approach has kept this complex docket moving despite its extraordinary volume.

As of 2026, the Plaintiffs' Steering Committee (PSC) in MDL 2873 includes firms that were appointed by the court to coordinate discovery and pretrial work on behalf of all plaintiffs. The PSC structure is standard in MDL proceedings of this scale.

Current MDL 2873 Track Structure:

*Attorney Insight: Attorneys handling these claims note that claimants whose injuries stem from military base AFFF exposure may have claims that proceed through the MDL's AFFF track rather than the drinking water track, and the distinction matters for which defendants are liable and which settlement funds apply.*

Litigation Watch: MDL 2873 is now managing three distinct litigation tracks simultaneously, and a claimant's correct placement on one of those tracks is the first determinative question in any PFAS case.

3M PFAS Settlement Update: $10.3 Billion Fund Details

The 3M Company's $10.3 billion settlement is the largest in the PFAS litigation. It was announced in June 2023 and covers claims brought by public water systems that detected PFAS in their water supplies.

Payments are structured over a 13-year period from 2023 through 2036. The settlement includes a minimum payment of $10.5 billion under revised terms, with potential for additional amounts tied to 3M's total PFAS-related expenses across all litigation.

The settlement does not cover individual personal injury claims. Water utilities, not individual residents, are the payees. Individual claimants pursuing compensation for cancer or illness must file through the personal injury track.

3M Settlement Key Terms:

*Attorney Insight: Attorneys handling these claims point to the 3M settlement as evidence that the company's internal documents on PFAS toxicology created unacceptable trial risk, leading to an early resolution designed to cap total exposure.*

DuPont PFAS Lawsuit Settlement: $1.185 Billion Fund Breakdown

DuPont de Nemours, Chemours, and Corteva Agriscience collectively agreed to pay $1.185 billion to resolve water utility claims related to PFAS contamination.

Chemours was spun off from DuPont in 2015 and manufactures GenX chemicals at its Fayetteville Works plant in North Carolina. Corteva was created in a separate 2019 DuPont corporate separation. The settlement allocates financial responsibility across all three entities.

The agreement covers drinking water system claims but excludes personal injury claims from individuals. Like the 3M agreement, DuPont and its related entities denied liability as part of the settlement terms.

DuPont/Chemours/Corteva Allocation:

*Attorney Insight: Attorneys handling these claims note that the DuPont corporate structure, involving multiple spinoffs over several years, was itself a subject of litigation as plaintiffs argued the separations were designed to shield assets from PFAS liability.*

Litigation Watch: The 3M and DuPont settlements together represent over $11 billion earmarked for water utilities, but they leave individual injury claimants outside both funds, pushing those cases further into the active MDL docket.

PFAS Settlement 2026: What the Distribution Phase Looks Like

In 2026, both the 3M and DuPont/Chemours/Corteva settlements are in active distribution. Water utilities that opted into the settlements and passed the eligibility threshold are receiving or will receive scheduled payments.

The claims administrator oversees distribution. Utilities must demonstrate that their water supplies contained PFAS at or above levels that qualify under the settlement terms. The EPA's April 2024 maximum contaminant level rule, setting a limit of 4 parts per trillion for PFOA and PFOS, is a relevant benchmark.

Individual claimants do not receive money from these utility settlement funds. The funds go to water systems to cover the cost of filtration infrastructure, remediation, and testing programs.

Settlement Distribution Timeline:

*Attorney Insight: Attorneys handling these claims point out that residents whose municipal water system receives settlement funds may still pursue personal injury claims if they were diagnosed with a PFAS-linked condition, because the utility payment does not extinguish individual injury rights.*

PFAS Lawsuit Who Qualifies: The Core Eligibility Test

A person generally qualifies for a PFAS personal injury claim if they meet two conditions: documented PFAS exposure and a diagnosis of a recognized PFAS-linked illness.

Exposure can be established through drinking water test records, proximity to a military base where AFFF was used, residence near a PFAS manufacturing facility, or occupational contact with PFAS products. Exposure duration matters. Courts and claims administrators look at years of contact, not a single incident.

The second condition is a qualifying diagnosis. Not every illness is recognized. The litigation has focused primarily on conditions with the strongest epidemiological evidence.

Primary Qualifying Conditions:

• Kidney cancer
• Bladder cancer
• Testicular cancer
• Thyroid disease
• Non-Hodgkin lymphoma
• Ulcerative colitis
• High cholesterol (in some claim categories)
• Pregnancy-induced hypertension and preeclampsia

*Attorney Insight: Attorneys handling these claims note that the strength of a qualifying claim depends heavily on the timeline between exposure and diagnosis, with longer documented exposure histories generally supporting stronger causation arguments.*

Bold Callout: A diagnosis alone is not enough. Both exposure and a qualifying illness must be established, and the exposure timeline must connect to the illness in a way that holds up under expert scrutiny.

PFAS Lawsuit Eligibility Requirements: Detailed Qualification Criteria

Eligibility in PFAS personal injury litigation involves more than a disease diagnosis. Courts and litigation managers assess several specific factors when evaluating whether a claim is viable.

The exposure source matters significantly. Plaintiffs claiming drinking water exposure need records showing contamination in their municipal supply or private well. Those claiming AFFF exposure need documentation of military service or employment at a site where AFFF was regularly used.

Geographic proximity is relevant but not standalone evidence. Living near a contaminated area supports exposure arguments when combined with water test data or biomonitoring results.

PFAS Eligibility Criteria Summary:

*Attorney Insight: Attorneys handling these claims note that blood serum PFAS testing, available through some environmental health clinics, can provide biological evidence of exposure where water records are incomplete or unavailable.*

Litigation Watch: Eligibility is not self-assessed. The specific combination of exposure documentation and medical diagnosis is evaluated on a case-by-case basis, and claims that appear qualifying often require expert review before filing.

Also worth exploring: Apple Watch Lawsuit 2026: Claims, Payouts, Updates

PFAS Cancer Lawsuit Compensation: Which Illnesses Drive the Largest Awards

Cancer diagnoses connected to PFAS exposure represent the strongest basis for the largest individual compensation amounts. The litigation's personal injury track has given particular weight to cancers with well-established epidemiological links to PFOA and PFOS.

Kidney cancer and bladder cancer have emerged as the top-tier conditions in terms of projected settlement value. This reflects both the seriousness of the diagnosis and the volume of scientific studies establishing the PFAS-to-cancer causal pathway.

Thyroid disease, ulcerative colitis, and elevated cholesterol are recognized conditions but typically carry lower projected compensation than cancer diagnoses.

Compensation Tier Framework (Personal Injury Track):

*Note: These are projected ranges based on mass tort precedent and litigation trajectory. Final individual amounts depend on case-specific factors.*

*Attorney Insight: Attorneys handling these claims point to the strength of the Parkinson Study (C8 Health Project) data linking specific PFAS compounds to cancer as a critical evidentiary foundation that has shaped which conditions receive the most litigation attention and the highest settlement values.*

PFAS Lawsuit Payout Amounts: What Individual Claimants Can Realistically Expect

The personal injury track payouts are not yet finalized in a global settlement, but litigation history in comparable mass torts provides a framework. Individual payout amounts in PFAS cases will depend on disease severity, age at diagnosis, documented exposure history, and individual economic damages.

A claimant with a stage-four kidney cancer diagnosis, 20-year exposure history through contaminated municipal water, and strong biomonitoring data is positioned differently than a claimant with a thyroid disorder and limited exposure documentation.

Medical costs, lost income, and pain-and-suffering calculations also factor into final figures. These individual damages components differentiate PFAS claims from one another in a way that prevents a single universal payout number.

Individual Claim Value Factors:

• Severity and stage of illness at diagnosis
• Age at diagnosis (younger claimants often receive higher economic loss calculations)
• Duration and intensity of documented PFAS exposure
• Strength of expert causation testimony
• State-specific damages caps (relevant if state court claims run parallel)
• Whether the claim resolves through global settlement or individual verdict

*Attorney Insight: Attorneys handling these claims note that the final payout structure for the personal injury track will likely mirror the tiered settlement model used in other major mass torts, such as the NFL concussion settlement, where condition severity and documented exposure drive the allocation formula.*

AFFF Lawsuit Update 2026: The Military Base Sub-Litigation

The AFFF track within MDL 2873 is a distinct litigation pathway. It covers individuals who were exposed to PFAS through aqueous film-forming foam, a firefighting agent used extensively at military bases, airports, and industrial facilities.

AFFF contains concentrated PFAS compounds and was used for decades in training exercises and emergency response. Personnel stationed at bases where AFFF was regularly used, as well as residents of communities near those bases, have filed claims alleging PFAS exposure and subsequent illness.

The AFFF track names different defendants than the drinking water track. AFFF manufacturers include 3M, Tyco Fire Products, Chemours, and BASF, among others. Some defendants settled certain claims while remaining active defendants on others.

Key AFFF Defendants:

*Attorney Insight: Attorneys handling these claims note that military veterans and civilian base employees may have stronger documented exposure histories than civilian water consumers, because military service records and base operational histories create a factual record that supports AFFF exposure claims with specificity.*

Litigation Watch: The AFFF track operates under separate case management orders from the drinking water track, and claimants with military or industrial AFFF exposure should confirm which track their case belongs to before any filing decisions are made.

PFAS Water Contamination Lawsuit: The Science Behind the Claims

PFAS are synthetic chemicals that do not break down in the environment or in the human body. That persistence is the scientific basis for the litigation. Once ingested, PFAS accumulate in blood, liver, and organs over time.

The most litigated compounds are PFOA (perfluorooctanoic acid) and PFOS (perfluorooctane sulfonate). The International Agency for Research on Cancer classified PFOA as a Group 1 carcinogen in 2023, meaning sufficient evidence exists to establish it causes cancer in humans. PFOS is classified as a possible human carcinogen.

This scientific backdrop is not peripheral to the litigation. It is the evidentiary core. Expert witnesses on both sides battle over dose-response relationships, exposure thresholds, and which specific health effects can be causally attributed to which PFAS compounds.

PFAS Science Fast Facts:

• PFOA classified as Group 1 carcinogen by IARC (2023)
• PFOS classified as possible human carcinogen
• EPA PFAS maximum contaminant levels: 4 parts per trillion for PFOA and PFOS (finalized April 2024)
• PFAS detected in drinking water supplies serving an estimated 200 million Americans
• Half-life in human blood: approximately 3 to 8 years depending on compound

*Attorney Insight: Attorneys handling these claims note that the IARC's 2023 upgrade of PFOA to a definitive carcinogen materially strengthened causation arguments in pending personal injury cases and may influence how quickly defense counsel moves toward global settlement on the personal injury track.*

PFAS Drinking Water Lawsuit States: Where the Litigation Is Most Active

PFAS contamination is a national problem, but certain states account for a disproportionate share of both contamination incidents and individual plaintiff filings. Military base proximity and industrial PFAS manufacturing history drive the geography of litigation.

Michigan, California, North Carolina, and New Jersey have among the highest concentrations of confirmed PFAS-contaminated drinking water systems. States near major military installations or legacy DuPont/Chemours manufacturing sites also show elevated claim volumes.

Several states have also filed their own government actions separate from MDL 2873. These state attorney general lawsuits run parallel to the federal MDL and can result in separate remediation funds that do not affect individual claimants' rights.

States With Highest PFAS Litigation Activity:

*Attorney Insight: Attorneys handling these claims note that West Virginia has a unique litigation history because the DuPont Washington Works facility in Parkersburg was the subject of the C8 class action decades earlier, creating a body of evidence that fed directly into the current MDL.*

PFAS Lawsuit How to File a Claim: The Process in 2026

Filing a PFAS personal injury claim in 2026 begins with retaining a mass tort or personal injury attorney. These cases are not filed individually through an online form. They require legal representation.

Once an attorney is retained, the case evaluation involves gathering exposure documentation, medical records, and geographic confirmation of contamination. The attorney files the case as part of the MDL proceeding in South Carolina or coordinates with the existing litigation track.

For claimants whose exposure stems from a municipal water source that already settled with 3M or DuPont, the personal injury claim is filed separately from any utility remediation payment. The two paths do not overlap.

PFAS Claim Filing Process:

1. Retain a mass tort attorney with PFAS/MDL 2873 experience
2. Gather medical records documenting diagnosis and treatment history
3. Obtain water contamination records for your municipality or private well
4. Provide military service records if AFFF exposure is claimed
5. Attorney files the case within the MDL or applicable state court
6. Case proceeds through the litigation track appropriate to your exposure type

*Attorney Insight: Attorneys handling these claims note that some firms are offering free case evaluations specifically for PFAS claimants, and the contingency fee model means qualified claimants typically pay no upfront legal fees.*

PFAS Lawsuit Filing Deadline 2026: Statutes of Limitations by State

The statute of limitations is the single most time-sensitive legal issue in any PFAS claim. Missing the deadline extinguishes the right to file regardless of the validity of the underlying claim.

PFAS statutes of limitations vary by state and by the nature of the claim. Personal injury claims in most states carry a two- to three-year window. The clock typically starts running from the date of diagnosis or the date the plaintiff knew or reasonably should have known that their illness was linked to PFAS exposure.

The discovery rule, which delays the limitations period until the plaintiff discovers the connection between their illness and PFAS, applies in most states but is not universal. Some states apply strict diagnosis-date rules.

Explore this too: AT&T Data Breach Lawsuit: Sign Up & Claim Guide 2026

Statute of Limitations by State (Personal Injury):

*Attorney Insight: Attorneys handling these claims strongly advise against waiting to consult counsel even if a diagnosis was recent, because gathering exposure documentation often takes months and the limitations period does not pause for case preparation.*

Litigation Watch: The statute of limitations is jurisdiction-specific and diagnosis-date-specific. A claimant who delays consulting an attorney by even six months may find their window closing before the case is ready to file.

PFAS Class Action Lawsuit 2026: Class Action vs. Mass Tort Distinction

PFAS claims are predominantly processed as a mass tort, not a traditional class action. Understanding the distinction matters. In a class action, all plaintiffs receive the same recovery based on a common injury. In a mass tort, each plaintiff's claim is evaluated individually.

MDL 2873 consolidates individual cases for pretrial purposes but does not convert them into a single class claim. Each plaintiff retains the right to their own individual trial or individual settlement negotiation.

The municipal water utility claims more closely resemble class-representative litigation because water systems collectively pursued similar remedies. Individual personal injury claims remain individual.

Class Action vs. Mass Tort Comparison:

*Attorney Insight: Attorneys handling these claims note that the mass tort structure is generally more favorable for individual cancer claimants than a class action would be, because it allows each claimant's specific illness severity and exposure history to drive their individual compensation rather than splitting a common fund equally.*

PFAS Lawsuit Timeline 2026: What Happens Next and When

The PFAS litigation's forward path runs through several predictable stages. The municipal water utility track is in distribution. The personal injury track is moving toward either a global settlement or continued bellwether trials, depending on how the litigation risks evolve.

The AFFF military track will likely be the last major segment to resolve. It involves more defendants, more complex exposure histories, and federal government interests that add procedural layers.

A reasonable projected timeline, based on the litigation's current posture and comparable mass tort histories, looks like this:

PFAS Litigation Forward Timeline:

*Attorney Insight: Attorneys handling these claims point to the Roundup glyphosate litigation as a comparable case: bellwether trials in that MDL established the plaintiff-favorable trial record that ultimately drove Bayer toward a multi-billion-dollar settlement even as individual cases kept being filed.*

Bold Callout: The PFAS litigation is not winding down in 2026. It is entering the phase where individual claimants with serious diagnoses face the most immediate decisions about whether and how to pursue compensation.

Frequently Asked Questions

What is the current status of the PFAS lawsuit in 2026?

MDL 2873 is active before Judge Richard M. Gergel in the U.S. District Court for the District of South Carolina.

The municipal water utility track is in settlement distribution, with payments from the 3M $10.3 billion fund and the DuPont/Chemours/Corteva $1.185 billion fund disbursing to qualifying water systems.

The personal injury track and AFFF military track remain active, with bellwether trials scheduled to shape the trajectory toward a global resolution.

Who qualifies to file a PFAS lawsuit claim?

Individuals who were exposed to PFAS through contaminated drinking water, AFFF firefighting foam, or proximity to a PFAS manufacturing or use site, and who were subsequently diagnosed with a recognized PFAS-linked illness, generally qualify.

Qualifying conditions include kidney cancer, bladder cancer, testicular cancer, thyroid disease, non-Hodgkin lymphoma, ulcerative colitis, and others.

Both exposure and diagnosis must be documented; one without the other is typically insufficient to sustain a viable claim.

How much compensation can PFAS claimants receive in 2026?

Individual payout amounts in the personal injury track are not finalized in a global settlement as of 2026, but projected ranges based on mass tort precedent span from approximately $25,000 for lower-tier conditions to over $500,000 for serious cancers with strong exposure documentation.

Final amounts depend on illness severity, exposure duration, age at diagnosis, and individual economic damages.

The municipal utility settlement funds pay water systems, not individuals, so residents seeking personal compensation must pursue separate personal injury claims.

What is the filing deadline for PFAS lawsuits in 2026?

There is no single universal deadline. Each state's statute of limitations governs personal injury claims, typically two to three years from the date of diagnosis or the date the plaintiff discovered the PFAS-illness connection.

Some claimants in states with two-year limitation periods who were diagnosed in 2024 may face 2026 deadlines.

Consulting a mass tort attorney promptly after a qualifying diagnosis is the most reliable way to protect filing rights.

What is the difference between the 3M settlement and the DuPont settlement?

Both settlements cover claims brought by public water systems, not individual injury claimants, and both defendants denied liability as terms of each agreement.

3M's settlement totals $10.3 billion paid over 13 years; DuPont, Chemours, and Corteva combined for $1.185 billion.

Neither fund compensates individuals directly for cancer or other personal injuries, which remain the subject of the ongoing personal injury track in MDL 2873.

How do I file a PFAS lawsuit claim if I was exposed through military service?

Claims arising from AFFF exposure at military bases are handled through the AFFF sub-track of MDL 2873, which involves different defendants than the drinking water track.

A mass tort attorney with experience in AFFF litigation will evaluate whether your service records, base assignment history, and medical diagnosis support a viable claim.

Veterans and civilian employees at military facilities should be aware that separate AFFF-specific defendants, including Tyco Fire Products and BASF, may be named in their claims rather than, or in addition to, 3M.

Closing

The PFAS litigation is the most consequential environmental mass tort of the current era. With over $11 billion already committed in utility-track settlements and the personal injury track still active, the case is far from its final chapter.

Individuals with qualifying diagnoses and documented PFAS exposure have a limited window to act. Statutes of limitations vary by state and are running. A mass tort or product liability attorney with MDL 2873 experience can assess whether a claim is viable before that window closes.

The decision to consult an attorney costs nothing under the contingency model. The decision to wait can cost everything.

Readers also liked: NCAA Lawsuit Settlement 2026: Payouts and Who Qualifies